Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (audio)

Highlights in Lung Cancer, 2013: MEK Inhibitors for KRAS Mutation-Positive NSCLC (audio)

From: GRACEcast
0 0 7 years ago
Dr. Natasha Leighl, Princess Margaret Hospital in Toronto, Canada, reviews exciting new data illustrating the potential benefits of the MEK inhibitor selumetinib in treating KRAS mutation-positive advanced non-small cell lung cancer.

Find us on Facebook